Clinical Trials Logo

Recurrent Gliosarcoma clinical trials

View clinical trials related to Recurrent Gliosarcoma.

Filter by:

NCT ID: NCT05465954 Recruiting - Clinical trials for Recurrent Gliosarcoma

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Start date: January 20, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

NCT ID: NCT05139056 Recruiting - Clinical trials for Recurrent Glioblastoma

Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effect of multiple doses of NSC-CRAd-S-pk7 in treating patients with high-grade gliomas that have come back (recurrent). NSC-CRAd-S-pk7 consists of neural stem cells that carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

NCT ID: NCT05039281 Recruiting - Clinical trials for Recurrent Glioblastoma

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Start date: September 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.

NCT ID: NCT05017610 Withdrawn - Clinical trials for Recurrent Glioblastoma

Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

Start date: October 20, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies the safety and feasibility of inducing a hypothyroxinemic state in patients with glioblastoma or gliosarcoma that has come back (recurrent). This trial aims to see if giving a specific thyroid hormone, such as methimazole and liothyronine, is safe and could benefit cancer treatment.

NCT ID: NCT04991870 Recruiting - Clinical trials for Recurrent Gliosarcoma

Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Glioblastoma

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial is to find out the best dose, possible benefits and/or side effects of engineered natural killer (NK) cells containing deleted TGF-betaR2 and NR3C1 (cord blood [CB]-NK-TGF-betaR2-/NR3C1-) in treating patients with glioblastoma that has come back (recurrent). CB-NK-TGF-betaR2-/NR3C1- cells are genetically changed immune cells that may help to control the disease.

NCT ID: NCT04854044 Withdrawn - Clinical trials for Recurrent Glioblastoma

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Start date: May 1, 2021
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effects of ONC201 in combination with standard of care radiation therapy in treating patients with glioblastoma that has come back (recurrent). ONC201 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy photons to kill tumors cells and shrink tumors. Giving ONC201 in combination with radiation therapy may help treat patients with recurrent glioblastoma.

NCT ID: NCT04477200 Recruiting - Clinical trials for Recurrent Glioblastoma

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Start date: August 5, 2020
Phase: Phase 1
Study type: Interventional

This is a phase 0/1 dose-escalation trial to determine the maximum tolerated dose of Mycophenolate Mofetil (MMF) when administered with radiation, in patients with glioblastoma or gliosarcoma.

NCT ID: NCT03896568 Recruiting - Clinical trials for Recurrent Glioblastoma

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Start date: February 12, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies best dose and side effects of oncolytic adenovirus DNX-2401 in treating patients with high-grade glioma that has come back (recurrent). Oncolytic adenovirus DNX-2401 is made from the common cold virus that has been changed in the laboratory to make it less likely to cause an infection (such as a cold). The virus is also changed to target brain cancer cells and attack them.

NCT ID: NCT03360708 Completed - Clinical trials for Recurrent Glioblastoma

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma

Start date: November 27, 2013
Phase: Early Phase 1
Study type: Interventional

This pilot early phase I trial studies the side effects of vaccine therapy in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy may work better in treating patients with glioblastoma.

NCT ID: NCT03283631 Terminated - Clinical trials for Recurrent Glioblastoma

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

INTERCEPT
Start date: May 30, 2018
Phase: Phase 1
Study type: Interventional

The goal of this protocol is to transfer autologous peripheral blood mononuclear cells (PBMCs) transduced with genes encoding a chimeric antigen receptor (CAR) that recognizes epidermal growth factor receptor variant III (EGFRvIII) tumor-specific antigen into patients with recurrent glioblastoma (GBM) following stereotactic radiosurgery (SRS). The CAR used is targeted to a tumor-specific mutation of the epidermal growth factor receptor, EGFRvIII, which is expressed on a subset of patients. Normal PBMCs derived from patients with GBM are genetically engineered with a viral vector encoding the CAR and infused directly into the patient's tumor with the aim of mediating regression of their tumors. Despite our CAR being targeted to a tumor specific antigen, given the prior toxicity using CARs that were not targeted to tumor-specific antigens, the investigators elected to begin with very low doses of cells. Enrollment on this study was suspended in April 2020 while an amendment to reduce the anticipated number of participants was under review and approved. The decision to terminate the study was made in January, 2021 to shift toward the next iteration of a related CAR T cell trial.